UAE Cracks Down on Unauthorised Regenerative Products. Will Other Countries Follow?
Regenerative aesthetics continues to evolve rapidly. Exosomes, PDRN, polynucleotides and growth factors are increasingly part of the conversation around skin quality, repair and rejuvenation.
But as new technologies enter the market, an equally important question is emerging: what exactly are we using, where has it come from, and what evidence supports it?
A recent regulatory development in the UAE has brought those questions sharply into focus.
What has happened?
In September 2026, the Emirates Drug Establishment (EDE) issued a warning concerning unauthorised medical products marketed as containing exosomes and/or PDRN for cosmetic, regenerative or therapeutic purposes.
Importantly, this is not a blanket ban on exosomes or PDRN. It relates specifically to products without the required EDE marketing authorisation, which are not authorised for importation, supply, sale, distribution or clinical use within the UAE.
The EDE states that for these unauthorised products, identity, source, composition, concentration, quality, sterility, purity, stability, effectiveness and safety cannot be assured. Potential concerns cited include contamination and infection, inflammatory or allergic reactions, inconsistent quality control, unsupported claims and uncertain long-term risks.
Why should practitioners pay attention?
While the circular applies specifically to the UAE, its wider message is relevant. “Regenerative”, “exosome”, “PDRN” or “growth factor” should never, on their own, be considered evidence of quality or efficacy.
Practitioners need to look beyond terminology to the individual product: its provenance, manufacturing, formulation, evidence and appropriate regulatory status.
It is also important to recognise that these technologies are not interchangeable. Growth factors, exosomes and PDRN represent different biological materials and approaches.
Why we work with AQ Skin Solutions
This distinction is particularly relevant to AQ Skin Solutions. AQ is not an exosome or PDRN proposition. Its technology is based around human fibroblast-derived conditioned media containing growth factors, cytokines and interleukins.
AQ reports patent protection for its technology across the US, European Union, Japan and Korea, alongside published scientific and clinical research relating to its growth-factor technology.
For Smart Group Medical, that matters. We chose to work with AQ because our approach to regenerative aesthetics has always been about more than following the latest trend. We want the practitioners we work with to have access to technology with established provenance, science behind its formulation and an evidence base they can explore and understand.
This isn't about declaring one entire regenerative category superior to another, nor does the EDE warning suggest all exosome or PDRN products are unsafe. It is about asking better questions of every product entering clinical practice.
As regenerative aesthetics enters its next chapter, innovation alone won't be enough. Credibility will matter just as much.


















